Sep 24 2007, 7:00 AM EST
News source: Business Wire
Pro-Pharmaceuticals, Inc. (Amex: PRW), a company "Advancing Drugs Through Glycoscience(R)", today announced that Theodore D. Zucconi, Ph.D, has been named President, a position previously held by David Platt, Ph.D., who will continue to serve as Chief Executive Officer and Chairman of the Board of Directors. Dr. Zucconi also has been nominated to serve on the Company's Board of Directors.
"Ted is a results-oriented leader with more than 35 years experience in operations management, R&D, problem solving, product development and strategic planning," said David Platt, Ph.D., Chief Executive Officer, Pro-Pharmaceuticals. "He is a creative, enthusiastic professional, with strong leadership qualities, and a history of increasing shareholder value. Ted's understanding of our technology will be invaluable as we move through our next growth phase."
"Pro-Pharmaceuticals is an excellent company, with an excellent team and a novel, leading-edge carbohydrate technology," said Dr. Zucconi. "I firmly believe in the wide application of the technology platform and the future of the company. I have enjoyed working with the team in the past and look forward to helping advance their product candidates to commercialization."
Dr. Zucconi is President, Implementation Edge, a management consulting firm that specializes in organizational performance improvement and has provided consulting services to organizations, including the National Nuclear Security Administration and Los Alamos National Laboratory. Previously, Dr. Zucconi held executive level positions in general management, technology and operations with divisions of Motorola. Prior to Motorola, Dr. Zucconi held technical, operational and scientific positions, with high technology companies including Nortel and IBM. Dr. Zucconi has developed more than 10 patented processes.
Dr. Zucconi received a Ph.D. in Analytical Chemistry from State University of New York, an M.S. in Analytical Chemistry, University of Connecticut, a B.S. in Chemistry, Villanova University, a Master's Certificate in International Management, Thunderbird University, and is designated a Certified Project Manager from Stanford University.
Pro-Pharmaceuticals, Inc. - Advancing Drugs Through Glycoscience(R)
Pro-Pharmaceuticals is a development stage pharmaceutical company engaged in the discovery, development and commercialization of first-in-class carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases. The Company's initial focus is the development and commercialization of a new generation of anti-cancer treatments using carbohydrate polymers to enhance the safety and efficacy of chemotherapy agents. The Company's technology capitalizes on the natural property of carbohydrates to increase the efficacy and reduce the toxicity of chemotherapeutics; "rescue" drugs that were shelved for toxicity or "half-life" issues; increase the solubility of existing drugs, and develop carbohydrate polymers as new chemical entities.
The Company has been conducting clinical and pre-clinical studies with its lead compound, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (Avastin(R)). Results show that DAVANAT(R) exhibits a broad spectrum of activity with tested drugs. The Company is developing additional carbohydrate-based therapeutic compounds that are currently in the pre-clinical stage of development. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing t
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All